

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177 and Bond code: 40150)**

**POSITIVE PROFIT ALERT**

This announcement is made by Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rules 13.09 and 37.47B(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board of directors of the Company (the “**Board**”) would like to inform the securities holders of the Company (the “**Securities Holders**”) and potential investors that the Group’s profit attributable to the owners of the parent for the year ended 31 December 2021 is expected to increase by over 4 folds as compared to last year to more than approximately RMB14,000 million (profit attributable to the owners of the parent for last year was RMB2,771 million). The substantial year-on-year increase in profit attributable to the owners of the parent was mainly attributable to: (1) the satisfactory performance of the Group’s principal business. During the year, sales of new products and high margin products increased, resulting in a notable year-on-year increase in overall revenue and gross profit margin of the Group; and (2) the strong financial performance of associates. The Group’s share of profits and losses of associates and a joint venture thus increased substantially as compared to last year.

The Company is still in the process of finalizing its results for the year ended 31 December 2021. The financial information contained in this announcement is solely based on a preliminary assessment by the management of the Company on the Company’s existing consolidated management accounts and is subject to finalization and adjustment, if any. Details of the financial information will be disclosed in the annual results announcement to be published by the Company on 31 March 2022.

**Securities Holders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 15 March 2022

*As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*